Thermo Fisher expands center to ease clinical trial logistics

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/ Hero Images)
(Image: Getty/ Hero Images)

Related tags: facility, Logistics, Clinical trial, Oncology, Gene therapy, Cell therapy

Thermo Fisher opened a new business center and biorepository along with an expanded distribution center, to help support mounting demand for clinical trial supply chain logistics.

Located in Frederick, Maryland, the site will serve as a hub for contract development and manufacturing organization (CDMO) Thermo Fisher’s business aiming to accommodate its future growth.

The facility expanded by more than 190,000 square feet making it the largest building on the company’s Frederick campus. With the expansion, another 22,000 square feet have been added to accommodate future advancements in automation. In total, Thermo Fisher’s investment in the campus has reached nearly $10m.

Additionally, the company added a 77,000 square foot facility, Cryo-Innovation Center and National Cancer Institute Repository for Clinical Trials. The center will be a third-party logistics site to support clinical trials as well as commercial cell and gene therapy developments. 

Dave Meadows, VP and general manager for Thermo Fisher Scientific said in a press release, “The Frederick campus will serve as Thermo Fisher’s clinical and commercial hub for cell and gene therapy treatments to meet the growing demand from the global healthcare industry.”

The new facility will act as a consolidation of several smaller facilities on the campus to create a center of excellence for clinical research sample storage. Central to the facility is a biorepository supporting the National Cancer Institute and its ongoing research.

Thermo Fisher recently stepped into a pilot program​ organized by the US Food and Drug Administration to advance policies in the drug development process. At the time a company representative told us that mitigation of risk and expediency needs to be the highest priority in all aspects of trial conduct. 

Related news

Show more

Related products

show more

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more